Pulmatrix (PULM) Accounts Payables (2014 - 2026)
Pulmatrix (PULM) posted Accounts Payables of $651000.0 for Q1 2026, up 139.34% sequentially from $272000.0 in Q4 2025, and down 0.91% YoY from $657000.0 in Q1 2025.
Pulmatrix (PULM) Accounts Payables (2014 - 2026) Analysis & Trends
Pulmatrix has reported Accounts Payables for 13 years, with the latest figure at $651000.0 in Q1 2026.
- Quarterly Accounts Payables fell 0.91% year-over-year to $651000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651000.0 (down 0.91% YoY) and the FY2025 annual result came in at $272000.0, down 66.38% from the prior year.
- Accounts Payables climbed to $651000.0 in Q1 2026 per PULM's latest filing, from $272000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.9 million in Q4 2023 and troughed at $69000.0 in Q3 2025.
- A 5-year average of $750352.9 and a median of $707000.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables jumped 61.2% in 2023, then slumped 81.5% in 2025.
- Over 5 years, Accounts Payables stood at $1.2 million in 2022, then surged by 61.2% to $1.9 million in 2023, then sank by 57.75% to $809000.0 in 2024, then sank by 66.38% to $272000.0 in 2025, then surged by 139.34% to $651000.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $651000.0, $272000.0, and $69000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | 529,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 529,000.00 |
| Mar 31, 2026 | 651,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 384,000.00 |
| Mar 31, 2025 | 657,000.00 |
| Dec 31, 2024 | 809,000.00 |
| Sep 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 393,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Dec 31, 2023 | 1.92 Mn |
| Sep 30, 2023 | 707,000.00 |
| Jun 30, 2023 | 929,000.00 |
| Mar 31, 2023 | 578,000.00 |
| Dec 31, 2022 | 1.19 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 728,000.00 |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 839,000.00 |
| Sep 30, 2021 | 875,000.00 |